Enhanced pathway reactivation in CRC relative to melanoma might be suggested as accounting in part for the differences clinically, however combined BRAF/MEK blockade is also highly effective in BRAF mutant lung cancer [13], a disease which like CRC is characteristically an EGFR expressing cancer [14]. This evidence concerns the gene MAP2K7 and lung carcinoma.